What's Hot
View all perspectives
Patricia Harkins DrTrishHarkins
2 years ago
🔥PrEP 4 SARS-CoV-2🔥
➡️casirivimab/imdevimab
⚡️Detection @ D1 and stabilisation up to D30 of serum and saliva Abs in IMID pts who failed response 2 COVID vax.
❓role in preventing severe infxn in high risk pts refractory 2 vax
#ACR22 @RheumNow Abst 2195 @Dr_David_Simon https://t.co/Zd00P5l363
Akhil Sood MD AkhilSoodMD
2 years ago
Abstr # 1878 looked at biomarkers assoc w/ MRI muscle inflammation in #IIM
- Of the potential cytokines, IL-7 strongly correlated with muscle damage on MRI thigh bilateral
@RheumNow #ACR22 #Myositis https://t.co/3i3C2EGtFM
Robert B Chao, MD doctorRBC
2 years ago
Smartphone app (FM-ACT) - self guided 8 chapters of structured lessons, mindfulness practices and activities w/ paced exercise and behavior change proved beneficial after 12 weeks.
Improvement in all areas: pain, sleep, psychological wellbeing
Abs#2235 @RheumNow #ACR22 https://t.co/wNhIw4pdJu
Bella Mehta bella_mehta
2 years ago
61pts with #FMF on Canakinumab - single center in Turkey
35% no attacks
attack frequency decreased in 55%
no response in 10%
- VAS score and inflammatory markers significantly improved
#ACR22 @RheumNow abst#1834
Olga Petryna DrPetryna
2 years ago
#abst0405 #ACR22 @RheumNow Post hoc of ph2/3 trials TOFA for AS: AEs/SAEs ⬆️ in pts w/BMI < 25 kg/m2 vs other BMI categories. Most frequent AEs (≥ 5% of pts) nasopharyngitis, URI& arthralgia. Δ from BL in LFTs similar, while % change from BL in lipid levels ⬆️ in Tofa vs PBO pts https://t.co/WmXD8uVK58
Dr. Rachel Tate uptoTate
2 years ago
Males w/ sarcoidosis may be more likely to have cardiac involvement. Patients treated with s/bDMARDs had a high response rate as reflected by clinical and imaging improvement. Abs 1846 @RheumNow #ACR22 https://t.co/ibbf4Dckun https://t.co/ZvGxPNFjwm
Dr. Rachel Tate uptoTate
2 years ago
In bio-naïve PsA pts on GUS, earlier improvements in self-reported health-related measures were sustained through 2 years. Abs 1850 #ACR22 @RheumNow https://t.co/6yhPesE3LZ https://t.co/nVCSgPgcqW
Md Yuzaiful Md Yusof Yuz6Yusof
2 years ago
#ACR22 Abstr#L07 Most impressive Delta difference vs Control in #lupus! In Phase 3 RCT in China, more patients in Telitacicept, BAFF/APRIL-i met SRI-4 (delta 44% if data imputed; 34% without). No major safety. Phase 3 in US is in progress. Would be historic! @RheumNow #ACRBest https://t.co/8wL2tkA8ym
Richard Conway RichardPAConway
2 years ago
Jonassen et al. AP1189, an oral melanocortin agonist in combination with MTX in early RA. Evidence of efficacy, no safety concerns. Looks promising! @RheumNow #ACR22 Abstr#1985 https://t.co/aK7BPwr5Ku https://t.co/9553KT2Pao
Richard Conway RichardPAConway
2 years ago
van Ouwerkerk et al. Glucocorticoid bridging in new RA associated higher risk of starting bDMARD (aHR 1.68) but not glucocorticoids (aHR 1) later in disease. Why? Maybe it shows what can be achieved? @RheumNow #ACR22 Abstr#1994 https://t.co/5GsXGMOZAm https://t.co/122CuSAqVw
Richard Conway RichardPAConway
2 years ago
Damart et al. Treatment strategies in CPP arthritis. Colchicine(1st line=73/86), MTX (second line=22/36), anakinra (n=27) and TCZ (n=25) most used. Drug survival MTX vs colchicine HR 0.64, TCZ vs anakinra HR 0.55 @RheumNow #ACR22 Abstr#1795 https://t.co/4PtxQNmTqV https://t.co/BKM4Ff9Gkk
Dr. Rachel Tate uptoTate
2 years ago
#ACR22 Abs 1863 Aromatase Inhibitor induced musculoskeletal inflammation observed independent of oophorectomy in novel mouse model, may not be E2 related as previously thought. @RheumNow https://t.co/XhUaGQX88p
Catherine Sims, MD DrCassySims
2 years ago
Are we asking women with IPAF about family planning?
Abstract #0944 #ACR22 @RheumNow
🫁 31 women
🤰83% had RF for adverse pregnancy outcomes
👼1/3 women had family plan. or birth control talks with pulm. docs
✋>50% women who saw a rheumatologist discussed these topics
Dr. Rachel Tate uptoTate
2 years ago
Rheum/ILD combined clinics may help dx ILD assoc'd CTD that is underdiagnosed currently. Pic below is very informative! Abs 1874 #ACR22 @RheumNow https://t.co/rr0QEfqicv https://t.co/V6eTyz1BuV
Dr. Rachel Tate uptoTate
2 years ago
Tofa may be option for pts w/ refractory skin predominant dermatomyositis. Abs 1887 #ACR22 @RheumNow https://t.co/heJ1kZeuPT https://t.co/CqK0dL7DQK
Poster Hall